GSK’s ViiV and Drug Patent Group agree settlement for HIV prevention

ViiV Healthcare, which is majority owned by GSK, and the Medicines Patent Group (MPP) have signed a brand new voluntary licensing settlement to develop entry to HIV prevention in creating international locations, GSK introduced.

The patent within the settlement pertains to long-acting cabotegravir (LA) for HIV pre-exposure prophylaxis (PrEP), the primary long-acting HIV prevention drug, to assist allow entry to underdeveloped, low-income, lower-middle-income and sub-African international locations. -Sahara.

As a part of the settlement, chosen generic producers may have the chance to develop, manufacture and provide a model of cabotegravir LA for PrEP in 90 international locations, topic to the required regulatory approvals.

Deborah Waterhouse, chief government officer at ViiV Healthcare, stated: “[This] represents a probably game-changing second in HIV prevention. Enabling scaled-up entry to generic cabotegravir LA for PrEP might play an essential position in stopping HIV transmission, notably amongst girls and adolescent women and serving to to finish the HIV epidemic.”

Based on the Joint United Nations Program on HIV/AIDS (UNAIDS), there are roughly 1.5 million new instances of HIV worldwide annually, most of which happen in resource-limited international locations, with girls and adolescent women disproportionately affected. Though oral PrEP therapy choices can be found in lots of international locations, their influence is proscribed in some populations because of challenges with adherence and stigma.

PrEP is an efficient therapy for HIV-negative at-risk folks to scale back their threat of an infection, however till just lately the therapy was solely obtainable as a each day dose capsule. Cabotegravir is the primary non-pill possibility, providing as much as two months of safety from a single intramuscular injection. Research additionally present it has the next effectiveness in comparison with oral tablets.

Commenting on the settlement, Charles Gore, government director of MPP, stated: “Lengthy-acting expertise opens up a brand new dimension that makes medicine simpler to take, and this product brings much-needed choices to these in danger… Fast entry to new expertise is the one our hope to realize the targets of the Sustainable Improvement Objectives.”

The announcement follows the world’s first regulatory approval of cabotegravir LA for PrEP by the US Meals and Drug Administration (FDA) final yr.

About the author


Leave a Comment